ClinicalTrials.gg
Active, not recruitingNCT06993610TibuSHIELDUpdated Oct 19, 2026

Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense

A Phase 2 interventional study of Tibulizumab Dose A and Tibulizumab Dose B in Hidradenitis Suppurativa (HS), sponsored by Zura Bio Inc. Active, not recruiting at 61 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Zura Bio Inc · Phase 2, Interventional, and Treatment

Updated Oct 19, 2026Primary completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.

Enrollment
27th of 139
247 · median 45
Started
2025
with 24 others
Phase 2
61 of 161
11 open now
Primary completion
2026-09
later than 8 of 54 live
Registered
135th of 161
by date

Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 27th largest by enrollment of the 139 interventional ones that give a count, is one of 25 that started in 2025, is one of 61 in phase 2, reaches primary completion later than 8 of the 54 other live ones, and was the 135th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 161 studies in Hidradenitis Suppurativa with a site in United States, or all of them as a file.
02

Study summary

The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)

03

Conditions studied

  • Hidradenitis Suppurativa (HS)

Keywords

  • Hidradenitis Suppurativa
  • HS
  • Tibulizumab
  • Hidradenitis Suppurativa clinical response
  • HiSCR
  • Skin Diseases
  • Inflammatory Skin Disease
  • Chronic Skin Condition
  • Sweat Gland Disease
  • Skin Diseases Bacterial
  • Suppurative Hidradenitis
  • Hidradenitis
  • Acne
  • Acne inversa
  • Inversa
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 to 70 years of age
  • ≥6-month history of Hidradenitis suppurativa (HS)
  • Total AN (abscess and inflammatory nodule) count ≥5
  • HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III

Exclusion criteria

Exclusion Criteria:

  • Draining tunnel count >20
  • Presence of another inflammatory condition or a skin condition that may interfere with study assessments
  • Known to have immune deficiency or is
  • Evidence or suspicion of active or latent tuberculosis
  • History of opportunistic, chronic, or recurrent infection requiring chronic antibiotic use, serious or life-threatening infection within 2 months, or had an infection requiring systemic antibiotics within 2 weeks
  • Has active systemic candidiasis
  • Unable to tolerate subcutaneous drug administration
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Tibulizumab Dose A

    Subcutaneous injection

    Biological: Tibulizumab Dose A

  • Experimental
    Tibulizumab Dose B

    Subcutaneous injection

    Biological: Tibulizumab Dose B

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Other: Placebo

Interventions

  • BiologicalTibulizumab Dose A

    Anti BAFF/IL-17 antibody. ZB-106

  • BiologicalTibulizumab Dose B

    Anti BAFF/IL-17 antibody. ZB-106

  • OtherPlacebo

    ZB-106 Placebo

06

What researchers measure

Primary outcomes

  1. [Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks

    AN count is calculated based on the sum of the abscesses and inflammatory nodules across different anatomical areas

    Time frame: Week 16

Secondary outcomes

  1. [Period 1] Achieving HiSCR50 at Week 16

    HiSCR50 is defined as at least a 50% decrease in total abscess and inflammatory nodule (AN) count with no increase from baseline in abscess and/or draining fistula count

    Time frame: Week 16

  2. [Period 1] Achieving HiSCR75 at Week 16

    HiSCR75 is defined as at least a 75% decrease in total abscess and inflammatory nodule (AN) count with no increase from baseline in abscess and/or draining fistula count

    Time frame: Week 16

  3. [Period 1] Absolute change from baseline in Dermatology Life Quality Index (DLQI) score at Week 16

    The DLQI is a validated general dermatology questionnaire that consists of 10 items that assess subject health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). Each item uses a scale from 0 (not at all) to 3 (very much), with a total score being the sum of each question. The higher the total score the more a patient's life is affected by their skin condition.

    Time frame: Week 16

  4. [Period 1] Absolute change from baseline in Patient's Global Assessment of Hidradenitis Suppurativa (HS-PtGA) score at Week 16

    The HS-PtGA is a single item measure that asks the individual to rate the overall impact of HS on their quality of life, capturing their comprehensive perception of disease severity and treatment response.

    Time frame: Week 16

  5. [Period 1] Absolute change from baseline in Skin Pain Numeric Rating Scale (NRS) at Week 16

    The Skin Pain NRS is a single-item measure in which the participant rates the worst level of skin pain in the previous 24 hours on a scale from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Week 16

  6. [Period 1] Safety and tolerability of tibulizumab

    Assessed by the incidence of all treatment-emergent adverse events (TEAEs), as well as changes from baseline in vital signs, electrocardiogram (ECG) parameters, and laboratory results.

    Time frame: Week 16

07

Study locations

61 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2026, 16 months.

Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 16 months is close to that.

Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.

Primary completion moved once since we started tracking on Sep 25, 2026: Nov 2026 → Sep 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 29, 2025
StartActual
May 16, 2025
Primary completionActual
Sep 18, 2026was Nov 2026
CompletionEst.
Apr 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Sep 18, 2026 (actual)
Oct 19, 2026
Enrollment
225 (estimated)→247 (actual)
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Primary completion Nov 2026→Sep 18, 2026 (now actual)
    Enrollment 225 (estimated)→247 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06993610
Lead sponsor
Zura Bio Inc
Responsible party
Sponsor
First posted
May 29, 2025
Start date
May 16, 2025
Primary completion
Sep 18, 2026
Completion
Apr 2027 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion